Pub Date : 2022-12-29DOI: 10.32352/0367-3057.6.22.05
С. О. Соловйов, Е. О. Стаховський, М. В. Лелека, Ф. В. Гладких
Prostate cancer is one of the most serious health problems encountered by the manhood of different countries of the world. Prostate cancer is a hormone-dependent tumor – growth and proliferation of both normal and cancer cells significantly depend on level of androgens. The analogues of gonadotropin-releasing hormone have been widely applied in prostate cancer therapy for more than 15 years. In Ukraine goserelin (1 month, 1 M; 3 months, 3 M) currently occupies the major part of market among the analogues of gonadotropin-releasing hormone. The alternative to goserelin is triptorelin (1 month, 1 M; 1 months, 3 M; 6 months, 6 M) – another well-studied and widely applied analogue of gonadotropin-releasing hormone, which is used for medical castration in cases of prostate cancer. Taking this into consideration, conducting the analysis of triptorelin and goserelin application is relevant. The purpose of the work was to conduct cost minimization and budget impact analysis using triptorelin 6 M and goserelin 3 M in hormonal therapy of prostate cancer in Ukrainian patients. The research was based on treatment cost of one patient during one year under condition of equivalent efficacy and safety of goserelin and triptorelin. The pharmacoeconomic analysis was conducted according to the «cost minimization» method. For calculation of direct costs when applying goserelin and triptorelin a pharmacoeconomic decision tree model was used, according to which the costs are computed with an allowance for possibilities and expenditures on side effects. The results of pharmacoeconomic modeling showed a tendency for a yearly cost cut in the amount of 2 887.69 UAH per patient when using triptorelin in model cohort which consisted of 1 000 patients. Besides, it allows 137 additional patients per thousand of them to be treated with triptorelin. As the result of modeling the influence on budget it was estimated that the amount of cost saving on buying triptorelin would average at 4,6 million UAH per every year for five years of its implementation. Hormone therapy with application of the analogues of gonadotropin-releasing hormone is one of the major treatment methods of patients with prostate cancer. A pharmacoeconomic analysis of triptorelin application in comparison with goserelin for treating patients with prostate cancer in Ukraine was conducted. The results of pharmacoeconomic modeling showed that a significant cost cut is expected when using triptorelin. It will allow additional patients, who need hormone therapy, to be treated.
{"title":"Cost minimization and budget impact analysis of the use of a new 6-month form of triptorelin in the treatment of patients with prostate cancer in Ukraine","authors":"С. О. Соловйов, Е. О. Стаховський, М. В. Лелека, Ф. В. Гладких","doi":"10.32352/0367-3057.6.22.05","DOIUrl":"https://doi.org/10.32352/0367-3057.6.22.05","url":null,"abstract":"Prostate cancer is one of the most serious health problems encountered by the manhood of different countries of the world. Prostate cancer is a hormone-dependent tumor – growth and proliferation of both normal and cancer cells significantly depend on level of androgens. The analogues of gonadotropin-releasing hormone have been widely applied in prostate cancer therapy for more than 15 years. In Ukraine goserelin (1 month, 1 M; 3 months, 3 M) currently occupies the major part of market among the analogues of gonadotropin-releasing hormone. The alternative to goserelin is triptorelin (1 month, 1 M; 1 months, 3 M; 6 months, 6 M) – another well-studied and widely applied analogue of gonadotropin-releasing hormone, which is used for medical castration in cases of prostate cancer. Taking this into consideration, conducting the analysis of triptorelin and goserelin application is relevant. \u0000The purpose of the work was to conduct cost minimization and budget impact analysis using triptorelin 6 M and goserelin 3 M in hormonal therapy of prostate cancer in Ukrainian patients. \u0000The research was based on treatment cost of one patient during one year under condition of equivalent efficacy and safety of goserelin and triptorelin. The pharmacoeconomic analysis was conducted according to the «cost minimization» method. For calculation of direct costs when applying goserelin and triptorelin a pharmacoeconomic decision tree model was used, according to which the costs are computed with an allowance for possibilities and expenditures on side effects. \u0000The results of pharmacoeconomic modeling showed a tendency for a yearly cost cut in the amount of 2 887.69 UAH per patient when using triptorelin in model cohort which consisted of 1 000 patients. Besides, it allows 137 additional patients per thousand of them to be treated with triptorelin. As the result of modeling the influence on budget it was estimated that the amount of cost saving on buying triptorelin would average at 4,6 million UAH per every year for five years of its implementation. \u0000Hormone therapy with application of the analogues of gonadotropin-releasing hormone is one of the major treatment methods of patients with prostate cancer. A pharmacoeconomic analysis of triptorelin application in comparison with goserelin for treating patients with prostate cancer in Ukraine was conducted. The results of pharmacoeconomic modeling showed that a significant cost cut is expected when using triptorelin. It will allow additional patients, who need hormone therapy, to be treated.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44809420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-29DOI: 10.32352/0367-3057.6.22.03
І. О. Власенко, Л. Л. Давтян
People with diabetes (PWD) are considered to be at high risk of developing severe influenza complications that can lead to hospitalization and sometimes death. It is because of the high risk of developing severe complications that WHO recommends seasonal influenza vaccination (SIV) for PWD. The purpose of the work is to establish the level of coverage of vaccination in PWD and to identify barriers to vaccination in this group in order to overcome obstacles. We analyzed data on the coverage of SIV in PWD and studied the problems of low adherence to vaccination in PWD. We used content analysis, bibliosemantic, analytical, generalizing analyses. An insufficient level of vaccination coverage of PWD has been established. Barriers to vaccination in PWD have been identified. Barriers can be: age, health status, allergic reactions and chronic diseases of people, lower level of education, gender and their employment in economic activities. At the same time, gaps in the knowledge of health care provider, insufficient involvement of endocrinologists and diabetologists in informing PWD about vaccination, a limited number of imported vaccines, and low physical and economic accessibility of vaccines negatively affect the coverage of SIV. A significant factor influencing the level of vaccination coverage of people is their vaccination hesitation. Pharmacists should actively participate in the vaccination campaign by raising public awareness and providing advice to PWD who regularly visit pharmacies. To increase the vaccination coverage of PWD, it is necessary to introduce training programs for doctors and pharmacists to attract them to influenza vaccination companies. Simultaneously conduct educational campaigns and education of PWD. It is advisable to organize a free flu vaccination in medical and diagnostic diabetic hospital (institutions) to increase the physical and economic accessibility of vaccination for PWD. A large number of studies showing the cost-effectiveness of SIV in PWD should be a significant factor for health authorities to improve measures to increase the level of coverage of SIV in patients in this risk group.
{"title":"Coverage of influenza vaccination of patients with diabetes and determination of barriers for implementation of vaccination","authors":"І. О. Власенко, Л. Л. Давтян","doi":"10.32352/0367-3057.6.22.03","DOIUrl":"https://doi.org/10.32352/0367-3057.6.22.03","url":null,"abstract":"People with diabetes (PWD) are considered to be at high risk of developing severe influenza complications that can lead to hospitalization and sometimes death. It is because of the high risk of developing severe complications that WHO recommends seasonal influenza vaccination (SIV) for PWD. \u0000The purpose of the work is to establish the level of coverage of vaccination in PWD and to identify barriers to vaccination in this group in order to overcome obstacles. \u0000We analyzed data on the coverage of SIV in PWD and studied the problems of low adherence to vaccination in PWD. We used content analysis, bibliosemantic, analytical, generalizing analyses. An insufficient level of vaccination coverage of PWD has been established. Barriers to vaccination in PWD have been identified. Barriers can be: age, health status, allergic reactions and chronic diseases of people, lower level of education, gender and their employment in economic activities. At the same time, gaps in the knowledge of health care provider, insufficient involvement of endocrinologists and diabetologists in informing PWD about vaccination, a limited number of imported vaccines, and low physical and economic accessibility of vaccines negatively affect the coverage of SIV. A significant factor influencing the level of vaccination coverage of people is their vaccination hesitation. Pharmacists should actively participate in the vaccination campaign by raising public awareness and providing advice to PWD who regularly visit pharmacies. To increase the vaccination coverage of PWD, it is necessary to introduce training programs for doctors and pharmacists to attract them to influenza vaccination companies. Simultaneously conduct educational campaigns and education of PWD. It is advisable to organize a free flu vaccination in medical and diagnostic diabetic hospital (institutions) to increase the physical and economic accessibility of vaccination for PWD. A large number of studies showing the cost-effectiveness of SIV in PWD should be a significant factor for health authorities to improve measures to increase the level of coverage of SIV in patients in this risk group.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47044904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-29DOI: 10.32352/0367-3057.6.22.01
О. В. Штрімайтіс, О. С. Кухтенко, В. І. Чуєшов
Acne is a common skin disease, which is accompanied by a significant skin and psychological burden. Today in Ukraine, significant attention is paid to the issue of acne treatment – scientists from leading scientific, medical (pharmaceutical) and cosmetic institutions are engaged in the search for the most optimal means for the acne treatment. Retinoids are a group of substances that deserves thorough study in terms of production and sustainable introduction of drugs to the pharmaceutical market of Ukraine. Therefore, the goal of our work was the marketing analysis of drugs for the treatment of acne with the content of retinoids as active substances. Determining the main trends of foreign manufacturers in the use of retinoids in medicinal products for the acne treatment will allow to predict approaches to the development of domestic effective medicine containing retinoids. During the analysis, methods of logical and meaningful formulation of the problem, office marketing research, content analysis of publications in scientific and practically oriented medical and pharmaceutical publications, comparative analysis, tabular and graphic means of visual presentation of the obtained data were used. The analysis of the range of drugs containing retinoids, presented on the domestic pharmaceutical market, was carried out according to the data of the State Register of Medicinal Products of Ukraine, the classification system of the ATC, and the State Formulary of Medicinal Products. According to the results of the work, it was determined that 13 trade names of medicinal products containing retinoids for the acne treatment are registered on the pharmaceutical market of Ukraine. It was determined that there are no registered medicinal products for the acne treatment containing retinoids of domestic production. In Ukraine medicines containing retinoids are represented by six countries. Among the dosage forms used for the acne treatment, solid dosage forms (hard and soft capsules) and soft dosage forms (gels, creams, lotions) should be distinguished. Today, the pharmaceutical market of Ukraine presents drugs of the I, III and IV generation of retinoids. Most of the drugs for the acne treatment containing retinoids registered in Ukraine are monocomponent. The lack of combinations of retinoids with active components widely used for the acne treatment is related to the technological aspects of the production of drugs with retinoids. The volume of sales of drugs with retinoids for the treatment of acne has been increasing in recent years, despite the high cost of products, which indicates the demand for the development of these drugs of domestic production. The obtained data will make it possible to develop approaches to the introduction into the production of domestic drugs for the treatment of acne containing retinoids.
{"title":"Marketing analysis of the use of drugs containing retinoids in the treatment of acne","authors":"О. В. Штрімайтіс, О. С. Кухтенко, В. І. Чуєшов","doi":"10.32352/0367-3057.6.22.01","DOIUrl":"https://doi.org/10.32352/0367-3057.6.22.01","url":null,"abstract":"Acne is a common skin disease, which is accompanied by a significant skin and psychological burden. Today in Ukraine, significant attention is paid to the issue of acne treatment – scientists from leading scientific, medical (pharmaceutical) and cosmetic institutions are engaged in the search for the most optimal means for the acne treatment. Retinoids are a group of substances that deserves thorough study in terms of production and sustainable introduction of drugs to the pharmaceutical market of Ukraine. \u0000Therefore, the goal of our work was the marketing analysis of drugs for the treatment of acne with the content of retinoids as active substances. \u0000Determining the main trends of foreign manufacturers in the use of retinoids in medicinal products for the acne treatment will allow to predict approaches to the development of domestic effective medicine containing retinoids. During the analysis, methods of logical and meaningful formulation of the problem, office marketing research, content analysis of publications in scientific and practically oriented medical and pharmaceutical publications, comparative analysis, tabular and graphic means of visual presentation of the obtained data were used. \u0000The analysis of the range of drugs containing retinoids, presented on the domestic pharmaceutical market, was carried out according to the data of the State Register of Medicinal Products of Ukraine, the classification system of the ATC, and the State Formulary of Medicinal Products. \u0000According to the results of the work, it was determined that 13 trade names of medicinal products containing retinoids for the acne treatment are registered on the pharmaceutical market of Ukraine. It was determined that there are no registered medicinal products for the acne treatment containing retinoids of domestic production. In Ukraine medicines containing retinoids are represented by six countries. Among the dosage forms used for the acne treatment, solid dosage forms (hard and soft capsules) and soft dosage forms (gels, creams, lotions) should be distinguished. Today, the pharmaceutical market of Ukraine presents drugs of the I, III and IV generation of retinoids. Most of the drugs for the acne treatment containing retinoids registered in Ukraine are monocomponent. The lack of combinations of retinoids with active components widely used for the acne treatment is related to the technological aspects of the production of drugs with retinoids. The volume of sales of drugs with retinoids for the treatment of acne has been increasing in recent years, despite the high cost of products, which indicates the demand for the development of these drugs of domestic production. The obtained data will make it possible to develop approaches to the introduction into the production of domestic drugs for the treatment of acne containing retinoids.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47622986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-29DOI: 10.32352/0367-3057.5.22.09
Я. О. Гриньків
Considering the high prevalence of migraine among women of reproductive age, the impact of this pathology on the state of health of the mother and the fetus, the selection of adequate pharmacotherapy is an extremely important process. Goal ‒ to analyze the possibility of using triptans registered on the pharmaceutical market of Ukraine for the treatment of migraine paroxysms in women during pregnancy on the basis of instructions, data from scientific literature, etc. Materials ‒ data from informational reference and scientific literature, State Register of Medicinal Products of Ukraine, UTIS. Research methods – webometric, comparative analyses; systematization of data. As of September 2022, eletriptan, zolmitriptan, rizatriptan, sumatriptan, frovatriptan are registered in Ukraine. The most complete information on the use of sumatriptan is presented in the instructions for «Sumamigren», «Antimigraine-Zdorovya». Summarized information from all the instructions: «The use of sumatriptan is possible only in cases where the expected benefit for the mother exceeds possible risks for the fetus». The information in the instructions for rizatriptan is practically identical for Rizamigren and Rizoptan, and for Rizatriptan-Pharmaten it is presented significantly more succinctly: «During pregnancy, should be used only in case of urgent need». The instructions for zolmitriptan «Zolmigren Spray» indicate: «use of the drug by pregnant women is possible only when the expected therapeutic effect for the woman exceeds the potential risk for the fetus/child». Domestic and foreign manufacturers of tablets indicate similar information. 1 medicine of frovatriptan is registered, where it is indicated: «The safety of the use of in pregnant women has not been established» and 1 medicine of eletriptan: «There is no experience of clinical use of in pregnant women». As of September 2022, the following medicines are registered in Ukraine: sumatriptan, rizatriptan, zolmitriptan, frovatriptan, eletriptan. Forms of release: tablets, tablets covered with a shell or a film shell, tablets dispersible in the oral cavity, capsules, dosed nasal spray. The content of the information in the instructions for the medical use of each triptan medicine taken separately for the analysis of the INN is similar, but not identical. Sumatriptan is considered the only relatively safe triptan for treatment of migraine paroxysms in pregnant women. A prospective direction for the development and expansion of the domestic pharmaceutical market of triptans is the registration of new release forms (and active substances (almotriptan, lasmiditan, naratriptan).
{"title":"5-HT1 receptor inhibitors (triptans) for the treatment of migraine during pregnancy: an analysis of the instructions for medical use","authors":"Я. О. Гриньків","doi":"10.32352/0367-3057.5.22.09","DOIUrl":"https://doi.org/10.32352/0367-3057.5.22.09","url":null,"abstract":"Considering the high prevalence of migraine among women of reproductive age, the impact of this pathology on the state of health of the mother and the fetus, the selection of adequate pharmacotherapy is an extremely important process. \u0000Goal ‒ to analyze the possibility of using triptans registered on the pharmaceutical market of Ukraine for the treatment of migraine paroxysms in women during pregnancy on the basis of instructions, data from scientific literature, etc. \u0000Materials ‒ data from informational reference and scientific literature, State Register of Medicinal Products of Ukraine, UTIS. Research methods – webometric, comparative analyses; systematization of data. \u0000As of September 2022, eletriptan, zolmitriptan, rizatriptan, sumatriptan, frovatriptan are registered in Ukraine. \u0000The most complete information on the use of sumatriptan is presented in the instructions for «Sumamigren», «Antimigraine-Zdorovya». Summarized information from all the instructions: «The use of sumatriptan is possible only in cases where the expected benefit for the mother exceeds possible risks for the fetus». The information in the instructions for rizatriptan is practically identical for Rizamigren and Rizoptan, and for Rizatriptan-Pharmaten it is presented significantly more succinctly: «During pregnancy, should be used only in case of urgent need». The instructions for zolmitriptan «Zolmigren Spray» indicate: «use of the drug by pregnant women is possible only when the expected therapeutic effect for the woman exceeds the potential risk for the fetus/child». Domestic and foreign manufacturers of tablets indicate similar information. 1 medicine of frovatriptan is registered, where it is indicated: «The safety of the use of in pregnant women has not been established» and 1 medicine of eletriptan: «There is no experience of clinical use of in pregnant women». \u0000As of September 2022, the following medicines are registered in Ukraine: sumatriptan, rizatriptan, zolmitriptan, frovatriptan, eletriptan. Forms of release: tablets, tablets covered with a shell or a film shell, tablets dispersible in the oral cavity, capsules, dosed nasal spray. The content of the information in the instructions for the medical use of each triptan medicine taken separately for the analysis of the INN is similar, but not identical. Sumatriptan is considered the only relatively safe triptan for treatment of migraine paroxysms in pregnant women. A prospective direction for the development and expansion of the domestic pharmaceutical market of triptans is the registration of new release forms (and active substances (almotriptan, lasmiditan, naratriptan).","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48362411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-29DOI: 10.32352/0367-3057.5.22.07
С. А. Котов, Т. М. Гонтова
Combinations of medicinal plants ensure the collective work of several active components, which can lead to an additive or synergistic effect. We have chosen the bur-marigold-calendula-hawthorn combination to obtain an antiallergic herbal medicine, in which the bur-marigold is the main plant, calendula is a helper plant that helps in the fight against accompanying symptoms, and hawthorn harmonizes the action of the first 2 plants. The aim of the work – the study of possible synergistic interactions in a multicomponent herbal antiallergic preparation by calculating the correlation between the content of polyphenols in various combinations of plant extracts and their antioxidant activity. Both individual extracts of a bur-marigold herb, calendula flowers and hawthorn leaves and flowers and a combined target extract with the ratio of herbal drugs (6:3:1) were obtained. Two and three component ompositions were obtained by mixing extracts in appropriate ratios. The content of polyphenols was determined by SPhU 2.0, 2.8.14. The antioxidant activity was determined by the neocuproin method. The Pearson Correlation was used to calculate the relationship between the content of polyphenols in extracts and their antioxidant activity. The maximum amount of polyphenols was found in the hawthorn extract (7.2%), in the bur-marigolg extract – 5.5%, and in the calendula extract – 3.4%. When adding calendula extract to the bur-marigold extract, the antioxidant activity was expected to decrease, thus an additive effect is observed; for the combination of bur-marigold /hawthorn 1:0.5, an increase in antioxidant activity (110.6%) was observed compared to the expected value, which may be synergism; for the combination of calendula/hawthorn, an increase in activity was observed. For 3-component combinations, it was found that only the combination of bur-marigold/calendula/hawthorn 1:0.5:0.5 showed greater activity (112%) than the target extract, all others combinations showed activity within the limits of possible variations (± 10%) of the components. When calculating the correlation between the content of polyphenols in the combinations and their activity using the Pearson coefficient, a strong positive correlation was found. The correlation between the content of polyphenols in various combinations of plant extracts and their antioxidant activity of a multicomponent herbal antiallergic preparation was studied. In 2-component combinations an additive effect was found when determining antioxidant activity, and an assumption was made about the ability of a synergism only for a combination of bur-marigold/hawthorn 1:0.5. All analyzed 3-component compositions showed antioxidant activity within the limits of possible variations (± 10%) of the components. A strong positive correlation was found between the content of polyphenols in the combinations and their activity.
{"title":"Study of the correlation between the content of polyphenols in different combinations of plant extracts and their antioxidant activity of a multicomponent herbal medicine with antiallergic effect","authors":"С. А. Котов, Т. М. Гонтова","doi":"10.32352/0367-3057.5.22.07","DOIUrl":"https://doi.org/10.32352/0367-3057.5.22.07","url":null,"abstract":"Combinations of medicinal plants ensure the collective work of several active components, which can lead to an additive or synergistic effect. We have chosen the bur-marigold-calendula-hawthorn combination to obtain an antiallergic herbal medicine, in which the bur-marigold is the main plant, calendula is a helper plant that helps in the fight against accompanying symptoms, and hawthorn harmonizes the action of the first 2 plants. \u0000The aim of the work – the study of possible synergistic interactions in a multicomponent herbal antiallergic preparation by calculating the correlation between the content of polyphenols in various combinations of plant extracts and their antioxidant activity. \u0000Both individual extracts of a bur-marigold herb, calendula flowers and hawthorn leaves and flowers and a combined target extract with the ratio of herbal drugs (6:3:1) were obtained. Two and three component ompositions were obtained by mixing extracts in appropriate ratios. The content of polyphenols was determined by SPhU 2.0, 2.8.14. The antioxidant activity was determined by the neocuproin method. The Pearson Correlation was used to calculate the relationship between the content of polyphenols in extracts and their antioxidant activity. \u0000The maximum amount of polyphenols was found in the hawthorn extract (7.2%), in the bur-marigolg extract – 5.5%, and in the calendula extract – 3.4%. When adding calendula extract to the bur-marigold extract, the antioxidant activity was expected to decrease, thus an additive effect is observed; for the combination of bur-marigold /hawthorn 1:0.5, an increase in antioxidant activity (110.6%) was observed compared to the expected value, which may be synergism; for the combination of calendula/hawthorn, an increase in activity was observed. For 3-component combinations, it was found that only the combination of bur-marigold/calendula/hawthorn 1:0.5:0.5 showed greater activity (112%) than the target extract, all others combinations showed activity within the limits of possible variations (± 10%) of the components. When calculating the correlation between the content of polyphenols in the combinations and their activity using the Pearson coefficient, a strong positive correlation was found. \u0000The correlation between the content of polyphenols in various combinations of plant extracts and their antioxidant activity of a multicomponent herbal antiallergic preparation was studied. In 2-component combinations an additive effect was found when determining antioxidant activity, and an assumption was made about the ability of a synergism only for a combination of bur-marigold/hawthorn 1:0.5. All analyzed 3-component compositions showed antioxidant activity within the limits of possible variations (± 10%) of the components. A strong positive correlation was found between the content of polyphenols in the combinations and their activity.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41620599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-29DOI: 10.32352/0367-3057.5.22.02
М. Б. Демчук, Н. В. Маланчук, Т. А. Грошовий
The prevalence of arterial hypertension is reaching alarming proportions in low- and middle-income countries, including Ukraine. A sufficiently high prevalence of hypertension among people of the working age creates an additional economic burden on the country's budget. Domestic and international clinical guidelines for the treatment of hypertension recommend to prefer using the combinations of drugs from different groups for the treatment of hypertension. Fixed combinations provide additional benefits for patients and healthcare programs, including simpler dosing regimens, improved adherence and better blood pressure control. The aim of this research was to analyze the dynamics of changes in the range of fixed combinations of antihypertensive drugs registered at the pharmaceutical market of Ukraine in 2022 compared to 2015. The object of the research was the data of the State Register of Medicinal Products of Ukraine for 2015 and 2022. The research was conducted using modern methods of analysis, systematization and generalization, mathematical and statistical calculations. According to the results of the retrospective analysis it was established that the total number of registered drugs increased by 28%. During the analyzed period, the assortment of the domestic market was supplemented with new combinations of antihypertensive drugs, which contribute to the qualitative and quantitative expansion of the assortment of combined antihypertensive drugs. In the analyzed period, there was a tendency to increase the share of medicines containing a fixed triple combination of active substances, which have antihypertensive effect, from 5.8% in 2015 to 13.6% of the assortment in 2022. The analysis of the assortment structure of combined antihypertensive drugs made it possible to establish a significant dominance of two groups, namely, angiotensin II receptor blockers in combination with diuretics (almost 27% of the assortment) and angiotensin-converting enzyme inhibitor with diuretics (from 36.1% to 20% of the assortment). According to the analysis, the dominance of foreign medicines at the pharmaceutical market of Ukraine was established. In 2015, the share of Ukrainian manufacturers was 26.45%, but the expansion of the range of drugs in the period until 2022 was provided by foreign manufacturing companies, which led to decrease in the share of domestic drugs to 17.3%. The analysis of the domestic market of combined antihypertensive drugs showed significant saturation and increase in the depth of the product range in the period to 2022. Nevertheless, it also made possible to establish the feasibility of creating and developing domestic combined antihypertensive drugs.
{"title":"Retrospective research of the range of combined antihypertensive drugs in Ukraine in 2022 compared to 2015","authors":"М. Б. Демчук, Н. В. Маланчук, Т. А. Грошовий","doi":"10.32352/0367-3057.5.22.02","DOIUrl":"https://doi.org/10.32352/0367-3057.5.22.02","url":null,"abstract":"The prevalence of arterial hypertension is reaching alarming proportions in low- and middle-income countries, including Ukraine. A sufficiently high prevalence of hypertension among people of the working age creates an additional economic burden on the country's budget. \u0000Domestic and international clinical guidelines for the treatment of hypertension recommend to prefer using the combinations of drugs from different groups for the treatment of hypertension. Fixed combinations provide additional benefits for patients and healthcare programs, including simpler dosing regimens, improved adherence and better blood pressure control. \u0000The aim of this research was to analyze the dynamics of changes in the range of fixed combinations of antihypertensive drugs registered at the pharmaceutical market of Ukraine in 2022 compared to 2015. \u0000The object of the research was the data of the State Register of Medicinal Products of Ukraine for 2015 and 2022. The research was conducted using modern methods of analysis, systematization and generalization, mathematical and statistical calculations. \u0000According to the results of the retrospective analysis it was established that the total number of registered drugs increased by 28%. During the analyzed period, the assortment of the domestic market was supplemented with new combinations of antihypertensive drugs, which contribute to the qualitative and quantitative expansion of the assortment of combined antihypertensive drugs. \u0000In the analyzed period, there was a tendency to increase the share of medicines containing a fixed triple combination of active substances, which have antihypertensive effect, from 5.8% in 2015 to 13.6% of the assortment in 2022. \u0000The analysis of the assortment structure of combined antihypertensive drugs made it possible to establish a significant dominance of two groups, namely, angiotensin II receptor blockers in combination with diuretics (almost 27% of the assortment) and angiotensin-converting enzyme inhibitor with diuretics (from 36.1% to 20% of the assortment). \u0000According to the analysis, the dominance of foreign medicines at the pharmaceutical market of Ukraine was established. In 2015, the share of Ukrainian manufacturers was 26.45%, but the expansion of the range of drugs in the period until 2022 was provided by foreign manufacturing companies, which led to decrease in the share of domestic drugs to 17.3%. \u0000The analysis of the domestic market of combined antihypertensive drugs showed significant saturation and increase in the depth of the product range in the period to 2022. Nevertheless, it also made possible to establish the feasibility of creating and developing domestic combined antihypertensive drugs.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45635702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-29DOI: 10.32352/0367-3057.5.22.08
М. В. Оглобліна, І. В. Бушуєва, В. В. Парченко
Today, 1,2,4-triazole derivatives are a promising class of organic compounds. This is caused, first of all, by the possibility of various chemical modifications of the 1,2,4-triazole fragment due to the addition of typical pharmacophores, which contributes to the expansion of the new molecules’ arsenal. A significant number of the 1,2,4-triazole derivatives show biological properties, that postively affects the further process of the most promising substances’ introduction. The aim of the work was to analyze the influence of various functional substituents of the new 1,2,4-triazole derivatives on the indicators of the mentioned compounds’ biological activity. Literature sources containing information on the influence of various functional substituents of the new 1,2,4-triazole derivatives on the indicators of these compounds’ biological activity became the research materials. Methods were used in the work: analytical, bibliosemantic information search, generalization. Triazoles and their heterocyclic analogues are compounds that contain a certain amount of Nitrogen atoms in their composition, showing the properties of typical pharmacophores. Their derivatives are easily synthesized and can be transformed into various biologically active molecules. Information on the 1,2,4-triazole derivatives’ chemical modeling, which allows for purposefully obtaining compounds with the necessary biological properties, taking into account the toxicity indicators of new molecules, has been analyzed and summarized. The authors have proved, that the gradual and predicted introduction of various substituents into the molecule of 1,2,4-triazole derivatives leads to the appearance of new types of biological activity, in some cases it gives an increase in already existing activity indicators. Chemical compounds’ modification due to the substituents’ changing around the 1,2,4-triazole fragment fundamentally changes the type of biological activity of new molecules. This approach was chosen by the majority of scientists as promising one for the new biologically active substances’ search among the 1,2,4-triazole derivatives. The priority, relevance and perspective of such researches have been proved by not only domestic scientists’ teams. Recently, foreign investigators from Turkey, India, Korea, China, Egypt, etc. have been actively searching for new biologically active substances among the 1,2,4-triazole derivatives. The analysis of modern literary sources on the study of the new 1,2,4-triazole derivatives’ biological activity allows us to establish certain features of the various functional substituents’ influence on the types of biological activity and convincingly proves the outlook of further synthetic tests in the compounds’ specified series.
{"title":"Review of the research on the influence of different functional substituents of new 1,2,4-triazole derivatives on the compounds biological properties","authors":"М. В. Оглобліна, І. В. Бушуєва, В. В. Парченко","doi":"10.32352/0367-3057.5.22.08","DOIUrl":"https://doi.org/10.32352/0367-3057.5.22.08","url":null,"abstract":"Today, 1,2,4-triazole derivatives are a promising class of organic compounds. This is caused, first of all, by the possibility of various chemical modifications of the 1,2,4-triazole fragment due to the addition of typical pharmacophores, which contributes to the expansion of the new molecules’ arsenal. A significant number of the 1,2,4-triazole derivatives show biological properties, that postively affects the further process of the most promising substances’ introduction. \u0000The aim of the work was to analyze the influence of various functional substituents of the new 1,2,4-triazole derivatives on the indicators of the mentioned compounds’ biological activity. \u0000Literature sources containing information on the influence of various functional substituents of the new 1,2,4-triazole derivatives on the indicators of these compounds’ biological activity became the research materials. Methods were used in the work: analytical, bibliosemantic information search, generalization. \u0000Triazoles and their heterocyclic analogues are compounds that contain a certain amount of Nitrogen atoms in their composition, showing the properties of typical pharmacophores. Their derivatives are easily synthesized and can be transformed into various biologically active molecules. \u0000Information on the 1,2,4-triazole derivatives’ chemical modeling, which allows for purposefully obtaining compounds with the necessary biological properties, taking into account the toxicity indicators of new molecules, has been analyzed and summarized. The authors have proved, that the gradual and predicted introduction of various substituents into the molecule of 1,2,4-triazole derivatives leads to the appearance of new types of biological activity, in some cases it gives an increase in already existing activity indicators. Chemical compounds’ modification due to the substituents’ changing around the 1,2,4-triazole fragment fundamentally changes the type of biological activity of new molecules. This approach was chosen by the majority of scientists as promising one for the new biologically active substances’ search among the 1,2,4-triazole derivatives. \u0000The priority, relevance and perspective of such researches have been proved by not only domestic scientists’ teams. Recently, foreign investigators from Turkey, India, Korea, China, Egypt, etc. have been actively searching for new biologically active substances among the 1,2,4-triazole derivatives. \u0000The analysis of modern literary sources on the study of the new 1,2,4-triazole derivatives’ biological activity allows us to establish certain features of the various functional substituents’ influence on the types of biological activity and convincingly proves the outlook of further synthetic tests in the compounds’ specified series.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45252429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-29DOI: 10.32352/0367-3057.5.22.01
І Організація, Управління Фармацією, Удк, тименту заводів
The war in Ukraine has not changed the epidemic situation with coronavirus disease (COVID-19). Further, new cases of disease and death among the population are recorded every day. A large number of people in shelters and bomb shelters, in transport during the evacuation, increases the risk of infection. One of the main complications that occur in patients with COVID-19 is the formation of blood clots, which can lead to negative consequences and death of the patient, and therefore, at the present stage, the use of anticoagulants in the form of low molecular weight heparins plays a very important role in the hospital treatment of coronavirus disease. Heparin potentially has advantages over other anticoagulants for its not only anticoagulant but also anti-inflammatory properties (reducing lung inflammation and improving oxygenation) and also has potential antiviral properties. The purpose of our study was to analyze the availability and range of anticoagulants used to treat coronavirus disease (COVID-19) and post-COVID syndrome in Ukraine. The materials of our study were the data of the State Register of Medicines, the Compendium directory, the Register of wholesale selling prices for medicines and the prices for anticoagulants in Lviv pharmacies. We have analyzed the domestic market of low molecular weight heparins used for the treatment of coronavirus disease (COVID-19) and post-covid syndrome according to the international non-proprietary name, taking into account all forms of production, manufacturers and prices. It has been established that in the pharmaceutical market of Ukraine these medicines are represented by 9 trade names, which in turn are divided according to the amount of active substance in 1 ml of solution. Analyzing the manufacturing companies, it was found that more than half (52.6%) of the presented heparins were produced in Ukraine, and 47.4% of the trade names of drugs are imported. The state of supply and prices for low molecular weight heparins in pharmacies in Lviv was analyzed. It has been established that the pharmacies of the city are provided with a sufficient amount of these medicines, manufacturers and dosages are widely represented. Although the current number of active patients coronavirus disease (COVID-19) in Ukraine has decreased compared to 2021, there is still a large number of patients who are treated with anticoagulants after an illness as a preventive measure or rehabilitation. There fore, the provision of pharmacies with a wide range of anticoagulant drugs in sufficient quantity and variety of dosage plays an important role in providing pharmaceutical assistance to the population in full.
{"title":"Overview of the pharmaceutical market of anticoagulants for the treatment of coronavirus disease (COVID-19) during marital state in Ukraine","authors":"І Організація, Управління Фармацією, Удк, тименту заводів","doi":"10.32352/0367-3057.5.22.01","DOIUrl":"https://doi.org/10.32352/0367-3057.5.22.01","url":null,"abstract":"The war in Ukraine has not changed the epidemic situation with coronavirus disease (COVID-19). Further, new cases of disease and death among the population are recorded every day. A large number of people in shelters and bomb shelters, in transport during the evacuation, increases the risk of infection. \u0000One of the main complications that occur in patients with COVID-19 is the formation of blood clots, which can lead to negative consequences and death of the patient, and therefore, at the present stage, the use of anticoagulants in the form of low molecular weight heparins plays a very important role in the hospital treatment of coronavirus disease. \u0000Heparin potentially has advantages over other anticoagulants for its not only anticoagulant but also anti-inflammatory properties (reducing lung inflammation and improving oxygenation) and also has potential antiviral properties. \u0000The purpose of our study was to analyze the availability and range of anticoagulants used to treat coronavirus disease (COVID-19) and post-COVID syndrome in Ukraine. \u0000The materials of our study were the data of the State Register of Medicines, the Compendium directory, the Register of wholesale selling prices for medicines and the prices for anticoagulants in Lviv pharmacies. \u0000We have analyzed the domestic market of low molecular weight heparins used for the treatment of coronavirus disease (COVID-19) and post-covid syndrome according to the international non-proprietary name, taking into account all forms of production, manufacturers and prices. \u0000It has been established that in the pharmaceutical market of Ukraine these medicines are represented by 9 trade names, which in turn are divided according to the amount of active substance in 1 ml of solution. Analyzing the manufacturing companies, it was found that more than half (52.6%) of the presented heparins were produced in Ukraine, and 47.4% of the trade names of drugs are imported. \u0000The state of supply and prices for low molecular weight heparins in pharmacies in Lviv was analyzed. It has been established that the pharmacies of the city are provided with a sufficient amount of these medicines, manufacturers and dosages are widely represented. \u0000Although the current number of active patients coronavirus disease (COVID-19) in Ukraine has decreased compared to 2021, there is still a large number of patients who are treated with anticoagulants after an illness as a preventive measure or rehabilitation. There fore, the provision of pharmacies with a wide range of anticoagulant drugs in sufficient quantity and variety of dosage plays an important role in providing pharmaceutical assistance to the population in full.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43408559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-29DOI: 10.32352/0367-3057.5.22.06
І. С. Даценко, А. В. Кабачна
Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by high blood pressure (hypertension) in the arteries of the lungs (pulmonary artery) for no apparent reason. Because symptoms are nonspecific and physical signs may be subtle, the disease is often diagnosed at late stages. Over the past few decades, significant progress has been made in the field of pulmonary arterial hypertension. Technological progress allows to diagnose the disease in the early stages, as well as to better assess the severity of the disease. Today, screening studies are becoming increasingly important to establish a clinical diagnosis and minimize lost opportunities without timely diagnosis, especially in patients with idiopathic PAH. Therefore, the issue of early diagnosis of patients with suspected PAH and confirmation of the diagnosis is a very important and urgent issue today. The objective of the paper: to study the methods of implementation of technologies for early diagnosis and pharmacotherapy of pulmonary arterial hypertension and conceptual presentation of the results of their implementation. The work used available scientific sources of information on the results of the implementation of diagnostic screening for early detection of PAH and pharmacotherapy in the world. The analysis of input data was carried out using systematic, documentary, informational and graphical research methods. The result of the analysis of information materials showed that over the past two decades, significant progress has been made in the treatment of PAH and more than doubled the survival rate of patients. It has been found that diagnostic screening is a relatively unique medical technology in relation to other medical interventions and can be defined as the systematic use of diagnostic technologies in individuals at risk to detect the disease before the onset of symptoms. The study proposes a systematic concept of economic evaluation of the diagnostic screening program for PAH to determine its optimal design. At the same time, this concept embodies the complex effect of the introduction of technologies for early diagnosis and pharmacotherapy of PAH, which is expressed in the positive dynamics of clinical indicators, reduced mortality and improved quality of life. It should be noted that a number of new tools and approaches for diagnostic screening give hope that advances in the diagnosis of PAH will also affect the effectiveness of medical care.
{"title":"Scientific substantiation of the concept of pharmacoeconomic analysis of technologies for early diagnosis and pharmacotherapy of pulmonary arterial hypertension","authors":"І. С. Даценко, А. В. Кабачна","doi":"10.32352/0367-3057.5.22.06","DOIUrl":"https://doi.org/10.32352/0367-3057.5.22.06","url":null,"abstract":"Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by high blood pressure (hypertension) in the arteries of the lungs (pulmonary artery) for no apparent reason. \u0000Because symptoms are nonspecific and physical signs may be subtle, the disease is often diagnosed at late stages. Over the past few decades, significant progress has been made in the field of pulmonary arterial hypertension. Technological progress allows to diagnose the disease in the early stages, as well as to better assess the severity of the disease. \u0000Today, screening studies are becoming increasingly important to establish a clinical diagnosis and minimize lost opportunities without timely diagnosis, especially in patients with idiopathic PAH. \u0000Therefore, the issue of early diagnosis of patients with suspected PAH and confirmation of the diagnosis is a very important and urgent issue today. \u0000The objective of the paper: to study the methods of implementation of technologies for early diagnosis and pharmacotherapy of pulmonary arterial hypertension and conceptual presentation of the results of their implementation. \u0000The work used available scientific sources of information on the results of the implementation of diagnostic screening for early detection of PAH and pharmacotherapy in the world. The analysis of input data was carried out using systematic, documentary, informational and graphical research methods. \u0000The result of the analysis of information materials showed that over the past two decades, significant progress has been made in the treatment of PAH and more than doubled the survival rate of patients. \u0000It has been found that diagnostic screening is a relatively unique medical technology in relation to other medical interventions and can be defined as the systematic use of diagnostic technologies in individuals at risk to detect the disease before the onset of symptoms. \u0000The study proposes a systematic concept of economic evaluation of the diagnostic screening program for PAH to determine its optimal design. \u0000At the same time, this concept embodies the complex effect of the introduction of technologies for early diagnosis and pharmacotherapy of PAH, which is expressed in the positive dynamics of clinical indicators, reduced mortality and improved quality of life. \u0000It should be noted that a number of new tools and approaches for diagnostic screening give hope that advances in the diagnosis of PAH will also affect the effectiveness of medical care.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69535099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-29DOI: 10.32352/0367-3057.5.22.05
А. І. Бойко, І. Ю. Рев’яцький
The computer pharmaceutical knowledge bases are effective tools of information support for the organization provision of medicines, pharmaceutical care and education of pharmaceutical specialists. The purpose of the work іs to substantiate the urgency of developing the computer pharmaceutical knowledge base «Pharmaceutical care for patients with diabetes» with increasing the number of the functional tasks of the information blocks of medicine provision management pharmaceutical care to patients with diabetes mellitus, didactic support of educational system of pharmacists in the conditions of various types of crisis situations. The objects of the study were the components of the information system about medicinal products, informational materials on the problems of pharmaceutical care for patients with diabetes mellitus during the period of the COVID-19 epidemic and the period of martial law. The methods of studying the need for information about medicines, pharmaceutical diagnostics, construction of information arrays of computer pharmaceutical knowledge bases were used. The following areas of expansion of the information arrays of blocks are substantiated: «Medicines» – inclusion of materials on new and classic drugs for the treatment of COVID-19; changes in the arsenal of antidiabetic drugs due to martial law; «Management of pharmaceutical care» – inclusion of systematized scientific data on the problem of specialization of information provision; «Reforming the health care system (pharmaceutical subsystem)» – adding information materials to optimize the management of the supply of antidiabetic drugs in view of the systematized measures overcoming the COVID-19 pandemic, epidemics of other genesis, anti-crisis measures in the health care system during the period of martial law; «Education of pharmaceutical specialists (postgraduate stage)» – filling with materials of provision of medicines and pharmaceutical care for patients with COVID-19 also have diabetes mellitus and during martial law. The structure of the computerized pharmaceutical knowledge base «Pharmaceutical care for patients with diabetes» was substantiated and the directions of its development were worked out in view of the expansion of functional tasks during the COVID-19 pandemic and martial law.
{"title":"Directions of development of functional missions of computer pharmaceutical knowledge bases talking into account various types of crisis situations","authors":"А. І. Бойко, І. Ю. Рев’яцький","doi":"10.32352/0367-3057.5.22.05","DOIUrl":"https://doi.org/10.32352/0367-3057.5.22.05","url":null,"abstract":"The computer pharmaceutical knowledge bases are effective tools of information support for the organization provision of medicines, pharmaceutical care and education of pharmaceutical specialists. \u0000The purpose of the work іs to substantiate the urgency of developing the computer pharmaceutical knowledge base «Pharmaceutical care for patients with diabetes» with increasing the number of the functional tasks of the information blocks of medicine provision management pharmaceutical care to patients with diabetes mellitus, didactic support of educational system of pharmacists in the conditions of various types of crisis situations. \u0000The objects of the study were the components of the information system about medicinal products, informational materials on the problems of pharmaceutical care for patients with diabetes mellitus during the period of the COVID-19 epidemic and the period of martial law. The methods of studying the need for information about medicines, pharmaceutical diagnostics, construction of information arrays of computer pharmaceutical knowledge bases were used. \u0000The following areas of expansion of the information arrays of blocks are substantiated: «Medicines» – inclusion of materials on new and classic drugs for the treatment of COVID-19; changes in the arsenal of antidiabetic drugs due to martial law; «Management of pharmaceutical care» – inclusion of systematized scientific data on the problem of specialization of information provision; «Reforming the health care system (pharmaceutical subsystem)» – adding information materials to optimize the management of the supply of antidiabetic drugs in view of the systematized measures overcoming the COVID-19 pandemic, epidemics of other genesis, anti-crisis measures in the health care system during the period of martial law; «Education of pharmaceutical specialists (postgraduate stage)» – filling with materials of provision of medicines and pharmaceutical care for patients with COVID-19 also have diabetes mellitus and during martial law. \u0000The structure of the computerized pharmaceutical knowledge base «Pharmaceutical care for patients with diabetes» was substantiated and the directions of its development were worked out in view of the expansion of functional tasks during the COVID-19 pandemic and martial law.","PeriodicalId":32942,"journal":{"name":"Farmatsevtichnii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47677497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：